Dr. Reddy’s Labs (RDY) Announces Settlement Agreement Related to Lipitor with Pfizer (PFE)
Tweet
Share
E-mailGet Alerts RDY Hot Sheet
Join SI Premium – FREE
Dr. Reddy’s Laboratories (NYSE: RDY) has entered into a settlement agreement with Pfizer (NYSE: PFE) which will resolve litigation related to Lipitor® Tablets, 10 mg, 20 mg, 40 mg, and 80 mg, known generically as Atorvastatin Calcium tablets. The terms of the agreement are confidential, and the agreement itself is subject to review by the U.S. Department of Justice and the Federal Trade Commission.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boeing names Ryan Shedd as new SVP and controller
- loanDepot receives NYSE non-compliance notice over stock price
- Elroy Air wins $46M U.S. Army contract for cargo drone system
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
